Previous Close | 2.0000 |
Open | 2.0020 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 1.8720 - 2.0020 |
52 Week Range | 1.8720 - 5.4260 |
Volume | |
Avg. Volume | 9,606 |
Market Cap | 303.957M |
Beta (5Y Monthly) | 1.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0600 |
Earnings Date | Nov 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-y
As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.